Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.

被引：6

作者：

Klempner, Samuel J.

Lee, Keun-Wook

Metges, Jean-Philippe

Catenacci, Daniel V. T.

Loupakis, Fotios

Ilson, David H.

Shah, Manish A.

Shitara, Kohei

Arozullah, Ahsan

Park, Jung Wook

Raizer, Jeffrey J.

Bang, Yung-Jue

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[3] Hop Morvan, Ctr Hosp Reg Univ Brest, Brest, France

[4] Univ Chicago, Gastrointestinal Oncol Program, Chicago, IL 60637 USA

[5] Univ Azienda Osped Univ Pisana, Pisa, Italy

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Weill Cornell Med Coll, New York, NY USA

[8] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[9] Astellas Pharma Global Dev Inc, Northbrook, IL USA

[10] Seoul Natl Univ, Coll Med, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e16063

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16063

引用

页数：3

共 50 条

[31] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Lordick, F.
Shah, M. A.
Shitara, K.
Ajani, J. A.
Bang, Y-J.
Enzinger, P. C.
Ilson, D. H.
Van Cutsem, E.
Plazas, J. Gallego
Huang, J.
Shen, L.
Oh, S. C.
Sunpaweravong, P.
Soo, H. H. F.
Turk, H. M.
Park, J. W.
Moran, D.
Bhattacharya, P.
Cao, Y. J.
Xu, R-H.
ANNALS OF ONCOLOGY, 2023, 34 : S1321 - S1321
[32] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Lordick, F.
Shah, M. A.
Shitara, K.
Ajani, J. A.
Bang, Y-J.
Enzinger, P. C.
Ilson, D. H.
van Cutsem, E.
Gallego Plazas, J.
Huang, J.
Shen, L.
Oh, S. C.
Sunpaweravong, P.
Soo, H. H. F.
Turk, H. M.
Park, J. W.
Moran, D.
Bhattacharya, P.
Cao, Y. J.
Xu, R-H.
ANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1524
[33] Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Bang, Y-J.
Shen, L.
Kang, Y-K.
Chao, Y.
Soo, H. H. F.
Sunpaweravong, P.
Moran, D.
Guerrero, A.
Li, R.
Pavese, J.
Matsangou, M.
Bhattacharya, P.
Shitara, K.
Xu, R-H.
ANNALS OF ONCOLOGY, 2023, 34 : S1527 - S1528
[34] Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Shitara, Kohei
Xu, Rui-Hua
Ajani, Jaffer A.
Moran, Diarmuid
Guerrero, Abraham
Li, Ran
Pavese, Janet
Matsangou, Maria
Bhattacharya, Pranob
Ueno, Yoko
Wang, Xuewei
Shah, Manish A.
GASTRIC CANCER, 2024, 27 (05) : 1058 - 1068
[35] Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).
Catenacci, Daniel V. T.
Park, Haeseong
Lockhart, A. Craig
Gold, Philip Jordan
Enzinger, Peter C.
Nordstrom, Jeffrey L.
Hong, Sam
Hochster, Howard S.
Kelly, Ronan Joseph
Uronis, Hope Elizabeth
Bendell, Johanna C.
Oh, Sang Cheul
Park, Se Hoon
Kim, Yeul Hong
Kang, Yoon-Koo
Lee, Keun-Wook
Ng, Matthew C. H.
Wigginton, Jon M.
Davidson-Moncada, Jan Kenneth
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[36] Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab plus chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.
Shitara, Kohei
Pophale, Rupesh
Matsangou, Maria
Park, Jung Wook
Oh, Mok
Bhattacharya, Pranob P.
Ranganath, Radhika
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 372 - 372
[37] Health-related quality of life (hrqol) in patients with claudin18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and
Lordick, F.
Van Cutsem, E.
Shitara, K.
Xu, R-H.
Ajani, J. A.
Shah, M. A.
Oh, M.
Ganguli, A.
Rhoten, S.
Bhattacharya, P.
Matsangou, M.
Park, J. W.
Kang, Y-K.
ANNALS OF ONCOLOGY, 2023, 34 : S860 - S861
[38] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Xu, Rui-hua
Arkenau, Hendrik-Tobias
Bang, Yung-Jue
Denlinger, Crystal S.
Kato, Ken
Tabernero, Josep
Wang, Jin
Li, Jiang
Castro, Henry
Moehler, Markus H.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[39] Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
Park, Wungki
O'Reilly, Eileen Mary
Furuse, Junji
Li, Chung-Pin
Oh, Do-Youn
Garcia-Carbonero, Rocio
Roth, Gael
Lee, Ho-Jin
Kunieda, Futoshi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] MetGastric: A randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction
Cunningham, David
Bang, Yung-Jue
Tabernero, Josep
Shah, Manish A.
Lordick, Florian
Hack, Stephen Paul
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →